{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:13:09Z","timestamp":1792782789256,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Palermo","id":[{"id":"https:\/\/ror.org\/044k9ta02","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Hereditary transthyretin amyloidosis (ATTRv) is a rare progressive, potentially life-threatening multisystem disorder caused by mutations in the transthyretin (TTR) gene, with variable penetrance and heterogeneous phenotypes, often leading to diagnostic delays, particularly in non-endemic regions. Identifying clinical \u201c\n                      <jats:italic>red flags<\/jats:italic>\n                      \u201d is crucial to shorten diagnostic latency. Machine learning (ML), a branch of artificial intelligence (AI), together with explainable artificial intelligence (XAI), offers novel opportunities to refine diagnostic algorithms and prioritize predictive features in ATTRv.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>A total of 452 patients who underwent TTR genetic testing between 2019 and 2024 in Sicily were retrospectively analyzed. Genetic testing was performed via polymerase chain reaction (PCR) and sequencing of TTR exons 2\u20134. Patients were stratified into Western and Eastern Sicily sub-cohorts to train and validate supervised ML models. Multiple algorithms were compared with hyperparameter tuning via GridSearch with cross-validation. Model interpretability was ensured using SHapley Additive exPlanations (SHAP) values and permutation importance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 452 patients, 68 (15%) carried a TTR mutation, 51.5% of whom were symptomatic. The most frequent red flags were sensory neuropathy (62.6%) and family history of cardiomyopathy (51.8%). Tree-based models outperformed other algorithms, with Random Forest selected for its optimal balance between precision and recall. Bilateral carpal tunnel syndrome, family history of neuropathy, and ataxia emerged as the most informative predictors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These findings suggest that integrating ML with clinical red flags may support the diagnostic decision-making process in patients referred for suspected ATTRv. However, these results should be considered exploratory and require validation in independent cohorts before clinical implementation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10072-026-09285-w","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:36:47Z","timestamp":1786513007000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of \u201cred flags\u201d in the diagnostic work-up of hereditary transthyretin amyloidosis: a study using a machine-learning approach"],"prefix":"10.1007","volume":"47","author":[{"given":"Antonia","family":"Pignolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Sajeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Magro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicasio","family":"Rini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Alonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Gerbino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfredi","family":"Parasporo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9805-1655","authenticated-orcid":false,"given":"Vincenzo","family":"Di Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Brighina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"issue":"4","key":"9285_CR1","doi-asserted-by":"publisher","first-page":"103019","DOI":"10.1016\/j.cpcardiol.2025.103019","volume":"50","author":"F Triposkiadis","year":"2025","unstructured":"Triposkiadis F et al (2025) Hereditary transthyretin amyloidosis (ATTRv). Curr Probl Cardiol 50(4):103019. https:\/\/doi.org\/10.1016\/j.cpcardiol.2025.103019","journal-title":"Curr Probl Cardiol"},{"key":"9285_CR2","doi-asserted-by":"publisher","first-page":"126021","DOI":"10.1016\/j.jns.2026.126021","volume":"488","author":"C Messina","year":"2026","unstructured":"Messina C (2026) From prevalence to precision: Interpreting neuropathy in transthyretin amyloidosis. J Neurol Sci 488:126021. https:\/\/doi.org\/10.1016\/j.jns.2026.126021","journal-title":"J Neurol Sci"},{"key":"9285_CR3","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2147\/PGPM.S359851","volume":"15","author":"V Di Stefano","year":"2022","unstructured":"Di Stefano V et al (2022) Italian real-life experience of patients with hereditary transthyretin amyloidosis treated with patisiran. Pharmgenomics Pers Med 15:499\u2013514. https:\/\/doi.org\/10.2147\/PGPM.S359851","journal-title":"Pharmgenomics Pers Med"},{"issue":"3","key":"9285_CR4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3390\/neurolint18030053","volume":"18","author":"C Messina","year":"2026","unstructured":"Messina C (2026) Treating the patient, not only the amyloid: symptomatic management in transthyretin amyloidosis. Neurol Int 18(3):53. https:\/\/doi.org\/10.3390\/neurolint18030053","journal-title":"Neurol Int"},{"issue":"7","key":"9285_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","volume":"15","author":"D Adams","year":"2019","unstructured":"Adams D, Koike H, Slama M, Coelho T (2019) Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol 15(7):387\u2013404. https:\/\/doi.org\/10.1038\/s41582-019-0210-4","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"9285_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/jns.12153","volume":"21","author":"I Concei\u00e7\u00e3o","year":"2016","unstructured":"Concei\u00e7\u00e3o I et al (2016) 'Red-flag\u2019 symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripheral Nerv Syst 21(1):5\u20139. https:\/\/doi.org\/10.1111\/jns.12153","journal-title":"J Peripheral Nerv Syst"},{"issue":"8","key":"9285_CR7","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41582-020-0377-8","volume":"16","author":"MA Myszczynska","year":"2020","unstructured":"Myszczynska MA et al (2020) Applications of machine learning to diagnosis and treatment of neurodegenerative diseases. Nat Rev Neurol 16(8):440\u2013456. https:\/\/doi.org\/10.1038\/s41582-020-0377-8","journal-title":"Nat Rev Neurol"},{"key":"9285_CR8","doi-asserted-by":"publisher","first-page":"109736","DOI":"10.1016\/j.yebeh.2024.109736","volume":"155","author":"K Han","year":"2024","unstructured":"Han K, Liu C, Friedman D (2024) Artificial intelligence\/machine learning for epilepsy and seizure diagnosis. Epilepsy Behav 155:109736. https:\/\/doi.org\/10.1016\/j.yebeh.2024.109736","journal-title":"Epilepsy Behav"},{"key":"9285_CR9","doi-asserted-by":"publisher","first-page":"7565","DOI":"10.3390\/s21227565","volume":"21","author":"V Kabade","year":"2021","unstructured":"Kabade V et al (2021) Machine learning techniques for differential diagnosis of vertigo and dizziness: a review. Sensors 21:7565. https:\/\/doi.org\/10.3390\/s21227565","journal-title":"Sensors"},{"key":"9285_CR10","doi-asserted-by":"publisher","first-page":"122799","DOI":"10.1016\/j.jns.2023.122799","volume":"455","author":"CM Smith","year":"2023","unstructured":"Smith CM, Weathers AL, Lewis SL (2023) An overview of clinical machine learning applications in neurology. J Neurol Sci 455:122799. https:\/\/doi.org\/10.1016\/j.jns.2023.122799","journal-title":"J Neurol Sci"},{"issue":"1","key":"9285_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/jns.12523","volume":"28","author":"D Hens","year":"2023","unstructured":"Hens D, Wyers L, Claeys KG (2023) Validation of an Artificial Intelligence driven framework to automatically detect red flag symptoms in screening for rare diseases in electronic health records: hereditary transthyretin amyloidosis polyneuropathy as a key example. J Peripheral Nerv Syst 28(1):79\u201385. https:\/\/doi.org\/10.1111\/jns.12523","journal-title":"J Peripheral Nerv Syst"},{"issue":"5","key":"9285_CR12","doi-asserted-by":"publisher","first-page":"805","DOI":"10.3390\/brainsci13050805","volume":"13","author":"V Di Stefano","year":"2023","unstructured":"Di Stefano V et al (2023) Machine learning for early diagnosis of ATTRv amyloidosis in non-endemic areas: a multicenter study from Italy. Brain Sci 13(5):805. https:\/\/doi.org\/10.3390\/brainsci13050805","journal-title":"Brain Sci"},{"key":"9285_CR13","doi-asserted-by":"publisher","unstructured":"Efron B, Tibshirani RJ (1994) An introduction to the bootstrap. Chapman and Hall\/CRC. https:\/\/doi.org\/10.1201\/9780429246593","DOI":"10.1201\/9780429246593"},{"key":"9285_CR14","doi-asserted-by":"publisher","unstructured":"Breiman L (2001) \"Random forests,\" mach learn. 45(1):5\u201332. https:\/\/doi.org\/10.1023\/A:1010933404324","DOI":"10.1023\/A:1010933404324"},{"key":"9285_CR15","doi-asserted-by":"publisher","unstructured":"Silva-Hern\u00e1ndez L, Horga Hern\u00e1ndez A, Valls Carb\u00f3 A, Guerrero Sola A, Montalvo-Moraleda MT, Gal\u00e1n D\u00e1vila L (2023) \u00abRed flags\u00bb en pacientes con polineuropat\u00eda amiloid\u00f3tica familiar relacionada con transtiretina (hATTR) en el momento del diagn\u00f3stico en un \u00e1rea no end\u00e9mica de Espa\u00f1a, Neurolog\u00eda. 38(2):87\u201392. https:\/\/doi.org\/10.1016\/j.nrl.2020.06.009","DOI":"10.1016\/j.nrl.2020.06.009"},{"issue":"10","key":"9285_CR16","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.jhsa.2019.06.016","volume":"44","author":"JP Donnelly","year":"2019","unstructured":"Donnelly JP, Hanna M, Sperry BW, Seitz WH (2019) Carpal tunnel syndrome: a potential early, red-flag sign of amyloidosis. J Hand Surg Am 44(10):868\u2013876. https:\/\/doi.org\/10.1016\/j.jhsa.2019.06.016","journal-title":"J Hand Surg Am"},{"issue":"10","key":"9285_CR17","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.1007\/s10072-023-06859-w","volume":"44","author":"JK van der Warendorf","year":"2023","unstructured":"Warendorf JK, van der Star GM, Dooijes D, Notermans NC, Vrancken AFJE (2023) Red flags and adjusted suspicion index for distinguishing hereditary transthyretin amyloid polyneuropathy from idiopathic axonal polyneuropathy. Neurol Sci 44(10):3679\u20133685. https:\/\/doi.org\/10.1007\/s10072-023-06859-w","journal-title":"Neurol Sci"},{"issue":"1","key":"9285_CR18","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/s13023-024-03304-9","volume":"19","author":"L Gal\u00e1n D\u00e1vila","year":"2024","unstructured":"Gal\u00e1n D\u00e1vila L et al (2024) A description of variant transthyretin amyloidosis (ATTRv) stage 1 patients and asymptomatic carriers in Spain: the EMPATIa study. Orphanet J Rare Dis 19(1):323. https:\/\/doi.org\/10.1186\/s13023-024-03304-9","journal-title":"Orphanet J Rare Dis"},{"key":"9285_CR19","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00415-025-13218-6","volume":"272","author":"PE Doneddu","year":"2025","unstructured":"Doneddu PE et al (2025) Prevalence of hereditary transthyretin amyloidosis in CIDP patients with red flags: a multicenter genetic screening and misdiagnosis analysis. J Neurol 272:515. https:\/\/doi.org\/10.1007\/s00415-025-13218-6","journal-title":"J Neurol"},{"key":"9285_CR20","doi-asserted-by":"publisher","unstructured":"Stefano VD et al (2024) Genetic screening for hereditary transthyretin amyloidosis with polyneuropathy in western Sicily: Two years of experience in a neurological clinic. Eur J Neurol 31(1). https:\/\/doi.org\/10.1111\/ene.16065","DOI":"10.1111\/ene.16065"},{"issue":"4","key":"9285_CR21","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3390\/brainsci15040365","volume":"15","author":"VD Stefano","year":"2025","unstructured":"Stefano VD et al (2025) Genetic screening for hereditary transthyretin amyloidosis in the population of cammarata and san giovanni gemini through red flags and registry archives. Brain Sci 15(4):365. https:\/\/doi.org\/10.3390\/brainsci15040365","journal-title":"Brain Sci"},{"issue":"2","key":"9285_CR22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3390\/jpm15020061","volume":"15","author":"C Messina","year":"2025","unstructured":"Messina C et al (2025) Expanding the genetic and clinical spectrum of hereditary transthyretin amyloidosis: The Glu61Ala Variant. J Pers Med 15(2):61. https:\/\/doi.org\/10.3390\/jpm15020061","journal-title":"J Pers Med"},{"issue":"s2","key":"9285_CR23","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.3233\/JND-150091","volume":"2","author":"A Mazzeo","year":"2015","unstructured":"Mazzeo A et al (2015) Transthyretin-related familial amyloid polyneuropathy (TTR-FAP): a single-center experience in Sicily, an Italian endemic area. J Neuromuscul Dis 2(s2):S39\u2013S48. https:\/\/doi.org\/10.3233\/JND-150091","journal-title":"J Neuromuscul Dis"},{"issue":"12","key":"9285_CR24","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1007\/s00415-013-7124-7","volume":"260","author":"MF Dohrn","year":"2013","unstructured":"Dohrn MF et al (2013) Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy. J Neurol 260(12):3093\u20133108. https:\/\/doi.org\/10.1007\/s00415-013-7124-7","journal-title":"J Neurol"},{"key":"9285_CR25","doi-asserted-by":"publisher","unstructured":"Gertz M et al (2020) Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC Fam Pract 21(1):198. https:\/\/doi.org\/10.1186\/s12875-020-01252-4","DOI":"10.1186\/s12875-020-01252-4"},{"key":"9285_CR26","doi-asserted-by":"publisher","first-page":"749","DOI":"10.2147\/TCRM.S185677","volume":"16,","author":"M Benson","year":"2020","unstructured":"Benson M, Dasgupta N, Rao R (2020) Diagnosis and screening of patients with hereditary transthyretin amyloidosis (hATTR): current strategies and guidelines. Ther Clin Risk Manag 16:749\u2013758. https:\/\/doi.org\/10.2147\/TCRM.S185677","journal-title":"Ther Clin Risk Manag"},{"key":"9285_CR27","doi-asserted-by":"publisher","unstructured":"Ceccanti M et al (2026) Deep phenotyping of <\u2009scp>F64L mutation in a multicentric cohort of patisiran-treated hereditary transthyretin amyloidosis patients (patisiranitaly). Eur J Neurol 33(6). https:\/\/doi.org\/10.1111\/ene.70657","DOI":"10.1111\/ene.70657"},{"key":"9285_CR28","doi-asserted-by":"publisher","first-page":"e078378","DOI":"10.1136\/bmj-2023-078378","volume":"385","author":"GS Collins","year":"2024","unstructured":"Collins GS et al (2024) TRIPOD\u2009+\u2009AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ 385:e078378. https:\/\/doi.org\/10.1136\/bmj-2023-078378","journal-title":"BMJ"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09285-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09285-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09285-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:34:12Z","timestamp":1791826452000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-026-09285-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["9285"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-09285-w","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"4 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The manuscript does not contain clinical studies or patient data.","order":1,"name":"Ethics","label":"Ethical standards","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"none declared.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no disclosures.","order":3,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"705"}}